Gastroenterologists Are Gearing Up to Incorporate Novel Oral Agents, Such As Pfizer’s Xeljanz, into the Treatment Paradigm for Ulcerative Colitis, According to Latest Data from Spherix Global Insights

March 23, 2018

Responsive image

EXTON, Pa., March 23, 2018 /PRNewswire/ — AbbVie’s Humira and Janssen’s Remicade have been the dominant agents in the moderate-to-severe ulcerative colitis market for years.  Recently, Takeda’s Entyvio has been gaining momentum, and survey results predict significant gains for Entyvio in…

Category: Precious Metals